Results 161 to 170 of about 85,025 (319)

Mechanism of Hypertriglyceridemia in Experimental Nephrosis

, 1989
Seiichi Furukawa, Tsutomu Hirano, Tomiko OHGOSHI, Seishi Nagano, Terumi Takahashi   +4 more
openalex   +2 more sources

Age at first childbirth and the risk of hypertriglyceridemia among Korean women [PDF]

, 2022
Hye Rin Choi, Hyeon Chang Kim
openalex   +1 more source

Glucagon‐Like Peptide‐1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 1, January 2026.
ABSTRACT Aims The use of glucagon‐like peptide‐1 (GLP1) analogues has increased due to benefits in glycaemic control, weight loss, and cardiorenal protection. However, concerns persist regarding their potential link to pancreatitis. We assessed this link in high‐risk patients with a history of pancreatitis or elevated lipase enzyme.
Bronya Calvarysky, Yaara Gal, Shiri Kushnir, Adi Turjeman, Tzippy Shochat, Idit Dotan, Talia Diker Cohen   +6 more
wiley   +1 more source

Effect of Fenofibrate Therapy on Blood Creatinine Levels in Patients with Hypertension and Hypertriglyceridemia

, 2013
Jun Hwan Cho, Young Hwan Choi, Cheol Won Hyeon, Kyung Joon Kim, Seonghyup Hyun, Jee Eun Kwon, Eun Young Kim, Wang Soo Lee, Kwang Je Lee, Sang‐Wook Kim, Tae Ho Kim, Chee Jeong Kim   +11 more
openalex   +1 more source

Hypertriglyceridemia-Induced Pancreatitis in Poorly Controlled Type 2 Diabetes [PDF]

, 2014
Hyun-Ho Jo, Kyu-Jin Kim, Bo‐Yeon Kim, Chan‐Hee Jung, Chul‐Hee Kim, Sung‐Koo Kang, Ji‐Oh Mok   +6 more
openalex   +1 more source

Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real‐World Assessment of Liver and Metabolic Health

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 1, January 2026.
Saroglitazar 4 mg daily for 6 months significantly improved liver stiffness, steatosis, and metabolic parameters in patients with MASLD in this prospective, real‐world study. The drug demonstrated meaningful regression of fibrosis and steatosis with stable BMI, highlighting its dual hepatic and metabolic benefits in MASLD management.
Mukulesh Gupta, Harshita Lachhwani, Kumar Praful Chandra, Rajiv Awasthi, Dinesh Kumar   +4 more
wiley   +1 more source

MON-132 DKA Accompanied with Concomitant Hypertriglyceridemia-Induced Acute Pancreatitis as Initial Presentation of Ketosis-Prone Diabetes

, 2019
Elio Paul Monsour, Frank Ramharrack
openalex   +1 more source

Hypertriglyceridemia-Induced Pancreatitis [PDF]

Journal of General Internal Medicine, 2015
Arjun, Gupta, Jedrek, Wosik, Steven, Philips   +2 more
openaire   +2 more sources

Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 1, January 2026.
Pooled data from randomised controlled trials demonstrate that supplementation with curcumin or turmeric leads to a significant reduction in systolic blood pressure (SBP) in individuals with prediabetes and type 2 diabetes. While the overall effect on diastolic blood pressure (DBP) was not significant, a pre‐specified subgroup analysis showed a ...
Hossein Bahari, Maryam Sharifi, Zahra Nejad Shahrokh Abadi, Mostafa Shahraki Jazinaki, Haniyeh Golafrouz, Zahra Asadi   +5 more
wiley   +1 more source

Aspirin Use Does Not Significantly Reduce the Risk of Liver Fibrosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease

Food Science &Nutrition, Volume 14, Issue 1, January 2026.
Our study did not find that aspirin significantly reduces the risk of liver fibrosis in patients with MASLD. Therefore, the long‐term use of aspirin solely for the prevention of liver fibrosis progression cannot be recommended in patients without high cardiovascular or cerebrovascular risk.
Linlin Yin, Bin Zhang
wiley   +1 more source